Praxis Medicines - PRAX Net earnings per share for the last four quarters

Praxis Precision Medicines (PRAX) is utilizing its reserve capital for costly anti-epileptic drug trials. The YoY TTM net income per share growth, with GURU.Markets data illustrated on this chart, has reached 0.80, reflecting the current level of the metric. The company is developing targeted therapies in collaboration with geneticists, competing in a patent-protected sector by leveraging the efficacy of small molecules.
PRAX (Praxis Precision Medicines): analytical breakdowns and indicator data

Praxis Precision Medicines is developing unique ion channel mapping platforms for the therapy of genetic CNS pathologies, establishing a long-term patent barrier. Analyzing the relative change in EPS YoY (TTM) allows for the smoothing of quarterly cost volatility by measuring the annual dynamics of earnings per share to identify the real profitability trend and assess business resilience under market pressure.